Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + Nab-paclitaxel in 2nd-line Cholangiocarcinoma
NCT05653817Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in cholangiocarcinoma (CCA), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Progression-Free Survival at 24 months. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05653817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653817.